Neurodegeneration – News and Features

Lilly to acquire exclusive rights to late-stage molecule for the treatment of multiple sclerosis.

The Neurologix procedure delivers a gene to quiet the abnormal brain activity that is correlated with motor deficits characterizing Parkinson’s disease.

The trial follows regulatory clearance from the French Health Products Safety Agency of the Company’s Clinical Trial Application.

Amyloid plaques, the hallmark of Alzheimer's disease, are clumps of fiber-like misfolded proteins which many experts think cause this neurodegenerative disease.

SGI claims that its Altix 64-Bit system improves genomic software applications performance up to 50 percent over 32-Bit systems.

The Company adds promising phase II neurology candidate and receives $8.1 million financing in connection with acquisition.

Appoints Ronen Tamir as Executive Vice President, Marketing and Communication.

The research involves fibroblast growth factor-2 (FGF-2), a naturally occurring protein that has been studied extensively for its neuroprotective properties.

The collaboration targets a non-dopaminergic approach to treating Parkinson’s disease.

Duke researchers have found a common variation in genes puts women who are under chronic stress at risk for increased depressive symptoms, but has the exact opposite effect in men.